



Grant Of Options

January 24, 2020 9:31 PM EST

Released : January 24, 2020 16:31

RNS Number : 9167A

MaxCyte, Inc.

24 January 2020

MaxCyte, Inc.

("MaxCyte" or the "Company")

Grant of Options

Gaithersburg, Maryland - 24 January 2020: MaxCyte (LSE: MXCT, MXCS), the global clinical-stage cell-based therapies and life sciences company, announces that on 20 January 2020, a total of 729,200 options of common stock in the Company ("Common Stock") were granted to PDMRs who are directors or officers of the Company ("Option Grants"). The annual 2020 grants were approved at a Board Meeting in December 2019, subject to issuance being following announcement of the Company's recent trading update ("Trading Update"). Details of the Option Grants are given below:

Option Grants to PDMRs	
Doerfler, Doug	390,200
Holtz, Ron	177,600
Thompson, J. Stark	26,900
Mandell, Art	26,900
Erck, Stan	26,900
Brooke, Will	26,900
Johnston, John	26,900
Douglas, Richard	26,900
Total	729,200

Options Grants to PDMRs vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 20 January 2020, of 136.00 pence (being the closing share price on the day of the Trading Update).

The information set out below is provided in accordance with the requirements of

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Names	<p>Doerfler, Doug</p> <p>Holtz, Ron</p> <p>Thompson, J. Stark</p> <p>Mandell, Art</p> <p>Erck, Stan</p> <p>Brooke, Will</p> <p>Johnston, John</p> <p>Douglas, Richard</p>
2	Reason for the notification	
a)	Position/status	<p>Doerfler, Doug - CEO and Director</p> <p>Holtz, Ron - CFO and Director</p> <p>Thompson, J. Stark - Non-executive Chairman</p> <p>Mandell, Art - Non-executive Director</p> <p>Erck, Stan - Non-executive Director</p> <p>Brooke, Will - Non-executive Director</p> <p>Johnston, John - Non-executive Director</p> <p>Douglas, Richard - Non-executive Director</p>
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	MaxCyte, Inc.

b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Grant of Options over Shares of Common Stock
b)	Identification code	US57777K1060
c)	Nature of the transactions	Grant of Options to PDMRs
d)	Price(s) and volume(s)	<p>Doerfler, Doug - 390,200 at an exercise price of 136.00 pence</p> <p>Holtz, Ron - 177,600 at an exercise price of 136.00 pence</p> <p>Thompson, J. Stark - 26,900 at an exercise price of 136.00 pence</p> <p>Mandell, Art - 26,900 at an exercise price of 136.00 pence</p> <p>Erck, Stan - 26,900 at an exercise price of 136.00 pence</p> <p>Brooke, Will - 26,900 at an exercise price of 136.00 pence</p> <p>Johnston, John - 26,900 at an exercise price of 136.00 pence</p> <p>Douglas, Richard - 26,900 at an exercise price of 136.00 pence</p>
d)	Aggregated information - Aggregated volume - Price	n/a

e)	Date of the transactions	20 January 2020
f)	Place of the transaction	Outside a trading venue

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. Through its life sciences business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its technology worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 100 partnered programme licenses in cell therapy with more than 70 licensed for clinical use. The Company has now signed eight clinical/commercial licenses with leading cell therapy developers and the potential pre-commercial milestones from these relationships now exceeds \$650 million. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. MaxCyte is also developing novel CARMA therapies, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. MaxCyte has established CARMA as a wholly owned subsidiary to facilitate independent investment and new partnerships to advance the CARMA platform. For more information, visit www.maxcyte.com

For further information, please contact:

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer +1 301 944 1660
Ron Holtz, Chief Financial Officer

Nominated Adviser and Joint Corporate Broker

Panmure Gordon +44 (0)20 7886 2500
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns

Joint Corporate Broker

Numis Securities Limited +44 (0)20 7260 1000
James Black
Duncan Monteith

Financial PR Adviser

Consilium Strategic Communications
Mary-Jane Elliott +44 (0)203 709 5700

Chris Welsh
Sukaina Virji

maxcyte@consilium-comms.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHBIMFTMTTBLM